About
Dr Mathew Suji Eapen is a Senior Scientist (Respiratory) at Mucpharm Pty Ltd, Sydney and a research associate for the Respiratory Translational Research Group at the University of Tasmania, Launceston.
He conducts discovery and basic research in lung diseases, including COPD, IPF, LAM, lung cancer, vaping effects, and COVID-19. Dr Eapen was awarded his PhD in Medical studies in 2018 from the University of Tasmania. He investigated the fundamental role of cellular changes in COPD and their effect on airway fibrosis.
Before his academic endeavours, Dr Eapen worked for ten years as a Senior Research Scientist in the pharmaceutical drug discovery industry. As an experimental pharmacologist, he worked on several projects on diseases such as breast cancer, COPD, IPF, psoriasis, and multiple sclerosis, among others.